Search hospitals > Indiana > Indianapolis
Indiana University/Melvin and Bren Simon Cancer Center
Claim this profileIndianapolis, Indiana 46202
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
917 reported clinical trials
43 medical researchers
Summary
Indiana University/Melvin and Bren Simon Cancer Center is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Cancer, Ovarian Cancer, Adult T-Cell Leukemia/Lymphoma and other specialties. Indiana University/Melvin and Bren Simon Cancer Center is involved with conducting 917 clinical trials across 604 conditions. There are 43 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Anita Turk, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Kathy Miller, MDIndiana University/Melvin and Bren Simon Cancer Center9 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
18 reported clinical trials
57 drugs studied
Nabil Adra, MDIndiana University Melvin and Bren Simon Cancer Center5 years of reported clinical research
Studies Prostate Cancer
Studies Prostatic Neoplasm
14 reported clinical trials
28 drugs studied
Shadia Jalal, MDIndiana University/Melvin and Bren Simon Cancer Center10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
23 drugs studied
Anita Turk, MDIU Health North Hospital6 years of reported clinical research
Studies Parotid Gland Cancer
Studies Colorectal Cancer
14 reported clinical trials
30 drugs studied
Clinical Trials running at Indiana University/Melvin and Bren Simon Cancer Center
Breast Cancer
Cancer
Lung Cancer
Small Cell Lung Cancer
Multiple Myeloma
Parotid Gland Cancer
Ovarian Cancer
Skin Cancer
Prostate Cancer
Adult T-Cell Leukemia/Lymphoma
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Indiana University/Melvin and Bren Simon Cancer Center?
Where is Indiana University/Melvin and Bren Simon Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Indiana University/Melvin and Bren Simon Cancer Center accept?
What awards or recognition has Indiana University/Melvin and Bren Simon Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.